Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1612 1624 1654 1675
This examiner grants 33% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17276711 | BIOLOGICAL BITS AS COMPUTABLE ELEMENTS WITHIN LIVING SYSTEMS | Non-Final OA | GEORGIA TECH RESEARCH CORPORATION |
| 18467797 | Compositions and Methods of Treatment Using CRRL 191 | Non-Final OA | Mayo Foundation for Medical Education and Research |
| 18551959 | MODIFIED PEPTIDOMIMETICS AND METHODS OF USE | Non-Final OA | The University of North Carolina at Chapel Hill |
| 17598761 | MIXTURES OF SYNTHETIC COPOLYPEPTIDE HYDROGELS | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18523645 | THERAPEUTIC USES OF DULAGLUTIDE | Final Rejection | Eli Lilly and Company |
| 18041815 | INSULIN RECEPTOR PARTIAL AGONISTS | Non-Final OA | Merck Sharp & Dohme LLC |
| 18334253 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING A VAGINAL INFECTION OF GARDNERELLA VAGINALIS | Non-Final OA | Massachusetts Institute of Technology |
| 18280400 | INHIBITORS OF CYSTEINE PROTEASES | Non-Final OA | The Board of Regents of the University of Texas System |
| 17789099 | ENHANCING EXPRESSION OF LINE-1 ENCODED ORF2P FOR CANCER THERAPEUTICS | Final Rejection | The Johns Hopkins University |
| 18251078 | COMPOSITIONS AND METHODS OF TREATING INFLAMMATORY LUNG DISEASES | Non-Final OA | Arizona Board of Regents on Behalf of the University of Arizona |
| 18019388 | ANTIMICROBIAL PEPTIDOMIMETICS | Final Rejection | UNIVERSITÄT ZÜRICH |
| 17786384 | METHOD FOR TREATING ANGELMAN SYNDROME AND RELATED DISORDERS | Final Rejection | Agency for Science, Technology and Research |
| 17998595 | CYCLOSPORINE ANALOGUES | Final Rejection | UCL BUSINESS LTD |
| 18585339 | GLP-1 RECEPTOR LIGAND MOIETY CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF | Final Rejection | Ionis Pharmaceuticals, Inc. |
| 18201129 | POLYPEPTIDE MODIFICATION AND CONJUGATION METHODS | Non-Final OA | Encodia, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy